Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Rite Aid defeats MedImpact in $200 million Elixir sale dispute

Published 06/24/2024, 01:59 PM
Updated 06/24/2024, 03:01 PM
© Reuters. FILE PHOTO: A Rite Aid store at 1841 North Western Avenue is shown at in Los Angeles, California, U.S., January 21, 2020.  REUTERS/Mike Blake/File Photo
CVS
-
WBA
-
US90274J5618=UBSS
-

By Dietrich Knauth

NEW YORK (Reuters) - MedImpact's attempt to recoup about $200 million related to its purchase of Rite Aid (NYSE:US90274J5618=UBSS)'s pharmacy benefit unit failed after a judge ruled on Monday that it took on Elixir's debts when it bought the company.

U.S. Bankruptcy Judge Michael Kaplan at a hearing in Trenton, New Jersey said that MedImpact was well aware that Elixir had been operating with a negative cash balance of about $200 million for about two years, due to reimbursement payments it owed to pharmacies including CVS Health (NYSE:CVS) and Walgreens Boots Alliance (NASDAQ:WBA)

Kaplan had previously approved MedImpact's $575 million purchase of Elixir, and he ruled that the sale agreement transferred those debts to the buyer.

Rite Aid, one of the largest U.S. pharmacy retailers, filed for bankruptcy in October citing its high debt, revenue declines, increased competition, and litigation over its role in the U.S. opioid crisis as factors that caused its bankruptcy.

The dispute with MedImpact, a pharmacy benefit manager, had threatened to derail Rite Aid's overall restructuring plan, which is up for approval at a final court hearing on Thursday, Kaplan said.

The judge noted that Rite Aid does not have cash to spare, and said MedImpact had no reason to believe Rite Aid was agreeing to cover Elixir's old debts at a time when it was desperately trying to raise cash and shed its own liabilities.

© Reuters. FILE PHOTO: A Rite Aid store at 1841 North Western Avenue is shown at in Los Angeles, California, U.S., January 21, 2020.  REUTERS/Mike Blake/File Photo

"It is no secret that money in this case is tight, and there is little wiggle room, let alone over $200 million of wiggle room," Kaplan said.

Rite Aid's bankruptcy plan would cut $2 billion in debt and provide $47.5 million to junior creditors, including individuals and local governments who have sued the company for allegedly ignoring possible red flags and illegally filling prescriptions for addictive opioid pain medication.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.